Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 16Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Sarcoma, Ewing 1Osteosarcoma 1Neuroblastoma 1Melanoma 1

Interventions

Cyclophosphamide 7Flow Cytometry 4fludarabine 3Therapeutics 3Polymerase Chain Reaction 3Nivolumab 3liposomal amphotericin B 2aldesleukin 2Voriconazole 2Psychiatric Rehabilitation 2Ondansetron 2Melphalan 2Itraconazole 2Ipilimumab 2Immunologic Techniques 2Etoposide 2Dexamethasone 2Caspofungin 2Carboplatin 2Calcium Dobesilate 2Busulfan 2Aprepitant 2Amplified Fragment Length Polymorphism Analysis 2Alemtuzumab 2tipifarnib 1sargramostim 1pembrolizumab 1lorukafusp alfa 1humanized 3F8 anti-GD2 monoclonal antibody 1fludarabine phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × humanized 3F8 anti-GD2 monoclonal antibody × Dermatologic × Clear all
NCT00743496 2017-08-17

A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma

St. Jude Children's Research Hospital

Phase 1 Completed
50 enrolled
CNSDermatologicSarcoma

Melanoma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡